SM
TBIO

Sabby Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Sabby Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,000
Closed -$152K – 153
2018
Q2 		$152K Buy
+12,000
New +$145K 0.02% 106

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Sabby Management's TBIO Position: Q3 2018 in Review

Sabby Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2018, closing a stake of 12,000 shares — an estimated $152K sold.

Sabby Management first reported a position in TBIO in Q2 2018 and held it in 1 quarter. The position peaked at $152K in Q2 2018. 48 funds tracked by Wall St. Rank hold TBIO as of Q3 2018.

  • Sabby Management reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Sabby Management sold 12,000 Translate Bio, Inc. Common Stock shares in Q3 2018, an estimated $152K.
  • Sabby Management first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Sabby Management's Translate Bio, Inc. Common Stock position peaked at $152K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2018.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.